There is an ongoing trial using CD19-BCMA dual CAR T-cell therapy in combination with Dasatinib in patients with r/r B-ALL, NHL including CLL, and multiple myeloma (NCT04603872). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.